Redmile Group, LLC Verve Therapeutics, Inc. Transaction History

Redmile Group, LLC

$822 Million
Q2 2025

A detailed history of Redmile Group, LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 740,261 shares of VERV stock, worth $8.24 Million. This represents 1.01% of its overall portfolio holdings.

Number of Shares

740,261

Previous 1,207,164 38.68%

Holding current value

$8.24 Million

Previous $5.52 Million 50.71%

% of portfolio

1.01%

Previous 0.58%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$2.97 - $11.38 $1.39 Million - $5.31 Million	-466,903 Reduced 38.68%	740,261 $8.31 Million
Q1 2025 May 15, 2025	SELL	$4.57 - $8.63 $507,270 - $957,930	-111,000 Reduced 8.42%	1,207,164 $5.52 Million
Q4 2024 Feb 14, 2025	SELL	$4.5 - $7.19 $293,409 - $468,802	-65,202 Reduced 4.71%	1,318,164 $7.43 Million
Q3 2024 Nov 14, 2024	SELL	$4.4 - $7.86 $352,176 - $629,114	-80,040 Reduced 5.47%	1,383,366 $6.7 Million
Q2 2024 Aug 14, 2024	SELL	$4.76 - $12.79 $671,678 - $1.8 Million	-141,109 Reduced 8.79%	1,463,406 $7.14 Million
Q1 2024 May 15, 2024	SELL	$10.81 - $17.96 $1.23 Million - $2.05 Million	-114,154 Reduced 6.64%	1,604,515 $21.3 Million
Q4 2023 Feb 14, 2024	BUY	$8.84 - $18.7 $5.81 Million - $12.3 Million	656,709 Added 61.84%	1,718,669 $24 Million
Q2 2023 Aug 14, 2023	SELL	$13.34 - $19.9 $783,311 - $1.17 Million	-58,719 Reduced 5.24%	1,061,960 $19.9 Million
Q1 2023 May 15, 2023	SELL	$14.3 - $24.01 $1.45 Million - $2.43 Million	-101,224 Reduced 8.28%	1,120,679 $16.2 Million
Q4 2022 Feb 14, 2023	SELL	$17.85 - $40.7 $5.06 Million - $11.5 Million	-283,223 Reduced 18.82%	1,221,903 $23.6 Million
Q3 2022 Nov 14, 2022	SELL	$15.63 - $41.49 $5.13 Million - $13.6 Million	-328,421 Reduced 17.91%	1,505,126 $51.7 Million
Q2 2022 Aug 15, 2022	SELL	$11.14 - $23.17 $19,840 - $41,265	-1,781 Reduced 0.1%	1,833,547 $28 Million
Q1 2022 May 16, 2022	BUY	$20.92 - $39.36 $2.65 Million - $4.99 Million	126,792 Added 7.42%	1,835,328 $41.9 Million
Q4 2021 Feb 14, 2022	SELL	$31.94 - $54.82 $5.13 Million - $8.8 Million	-160,494 Reduced 8.59%	1,708,536 $63 Million
Q3 2021 Nov 15, 2021	SELL	$46.0 - $73.99 $3.11 Million - $4.99 Million	-67,500 Reduced 3.49%	1,869,030 $87.8 Million
Q2 2021 Aug 16, 2021	BUY	$31.92 - $60.25 $61.8 Million - $117 Million	1,936,530 New	1,936,530 $117 Million

Others Institutions Holding VERV

# of Institutions

195

Shares Held

72.2M

Call Options Held

452K

Put Options Held

2.96M

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $667M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.

Account

Redmile Group, LLC Verve Therapeutics, Inc. Transaction History